default author photo

Huiyang Shi

affiliation not provided to SSRN

  • affiliation not provided to SSRN

SCHOLARLY PAPERS

1

DOWNLOADS

27

TOTAL CITATIONS

0

Scholarly Papers (1)

Actions:
Email selected abstracts
1.

Efficacy and safety of furmonertinib plus anlotinib as first-line treatment for locally advanced or metastatic NSCLC patients: a single-arm, phase I/II trial

Number of pages: 33 Posted: 08 Sep 2025
Huiyang Shi, Haohua Zhu, Le Tang, Jingyu Lu, Kai Zhu, Miaohan Wang, Xingsheng Hu and Yuankai Shi
affiliation not provided to SSRN, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN and Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC) - Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs
Downloads 27 (1,359,097)

Abstract:

Loading...

Furmonertinib, Anlotinib, First-line treatment, NSCLC, Epidermal growth factor receptor